Clinical Trials Directory

Trials / Conditions / B-cell Malignancy

B-cell Malignancy

15 registered clinical trials studyying B-cell Malignancy — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants
NCT06634589
BeOne MedicinesPhase 1 / Phase 2
RecruitingUniversal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
NCT06662227
Wondercel Biotech (ShenZhen)EARLY_Phase 1
RecruitingAnti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
NCT06532630
Shanghai First Song Biotechnology Co., LTDEARLY_Phase 1
RecruitingAS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363
Carna Biosciences, Inc.Phase 1
RecruitingA Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
NCT05643742
CRISPR Therapeutics AGPhase 1 / Phase 2
RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P
NCT05294731
BeiGenePhase 1 / Phase 2
UnknownSafety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
NCT05106907
Fundamenta Therapeutics, Ltd.Phase 1
UnknownSafety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
NCT05106946
Fundamenta Therapeutics, Ltd.Phase 1
RecruitingA Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716
BeOne MedicinesPhase 1 / Phase 2
UnknownSafety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
NCT04601181
Fundamenta Therapeutics, Ltd.Phase 1
UnknownSafety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
NCT04384393
Fundamenta Therapeutics, Ltd.Phase 1
CompletedCD19-CAR-T in B-cell Malignancies Patients
NCT03952923
Hebei Yanda Ludaopei HospitalPhase 1
TerminatedA Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CAR
NCT04035434
CRISPR Therapeutics AGPhase 1 / Phase 2
CompletedCD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients
NCT03953599
Hebei Yanda Ludaopei HospitalPhase 1
UnknownCD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
NCT03559439
Shanghai Tong Ren HospitalPhase 1